Home

Download Recombinant Vesicular Stomatitis Virus Vaccine Vectors Expressing Filovirus Glycoproteins Lack Neurovirulence in Nonhuman Primates Ebook, PDF Epub


📘 Read Now     â–¶ Download


Recombinant Vesicular Stomatitis Virus Vaccine Vectors Expressing Filovirus Glycoproteins Lack Neurovirulence in Nonhuman Primates

Description Recombinant Vesicular Stomatitis Virus Vaccine Vectors Expressing Filovirus Glycoproteins Lack Neurovirulence in Nonhuman Primates.

Detail Book

  • Recombinant Vesicular Stomatitis Virus Vaccine Vectors Expressing Filovirus Glycoproteins Lack Neurovirulence in Nonhuman Primates PDF
  • Recombinant Vesicular Stomatitis Virus Vaccine Vectors Expressing Filovirus Glycoproteins Lack Neurovirulence in Nonhuman Primates EPub
  • Recombinant Vesicular Stomatitis Virus Vaccine Vectors Expressing Filovirus Glycoproteins Lack Neurovirulence in Nonhuman Primates Doc
  • Recombinant Vesicular Stomatitis Virus Vaccine Vectors Expressing Filovirus Glycoproteins Lack Neurovirulence in Nonhuman Primates iBooks
  • Recombinant Vesicular Stomatitis Virus Vaccine Vectors Expressing Filovirus Glycoproteins Lack Neurovirulence in Nonhuman Primates rtf
  • Recombinant Vesicular Stomatitis Virus Vaccine Vectors Expressing Filovirus Glycoproteins Lack Neurovirulence in Nonhuman Primates Mobipocket
  • Recombinant Vesicular Stomatitis Virus Vaccine Vectors Expressing Filovirus Glycoproteins Lack Neurovirulence in Nonhuman Primates Kindle


Book Recombinant Vesicular Stomatitis Virus Vaccine Vectors Expressing Filovirus Glycoproteins Lack Neurovirulence in Nonhuman Primates PDF ePub

Recombinant Vesicular Stomatitis Virus Vaccine Vectors ~ Recombinant Vesicular Stomatitis Virus Vaccine Vectors Expressing Filovirus Glycoproteins Lack Neurovirulence in Nonhuman Primates The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters Citation Mire, Chad E., Andrew D. Miller, Angela Carville, Susan V.

Recombinant vesicular stomatitis virus vaccine vectors ~ The filoviruses, Marburg virus and Ebola virus, cause severe hemorrhagic fever with high mortality in humans and nonhuman primates. Among the most promising filovirus vaccines under development is a system based on recombinant vesicular stomatitis virus (rVSV) that expresses an individual filovirus glycoprotein (GP) in place of the VSV glycoprotein (G).

Recombinant Vesicular Stomatitis Virus Vaccine Vectors ~ Recombinant Vesicular Stomatitis Virus Vaccine Vectors Expressing Filovirus Glycoproteins Lack Neurovirulence in Nonhuman Primates March 2012 PLoS Neglected Tropical Diseases 6(3):e1567

Recombinant Vesicular Stomatitis Virus Vaccine Vectors ~ Abstract. The filoviruses, Marburg virus and Ebola virus, cause severe hemorrhagic fever with high mortality in humans and nonhuman primates. Among the most promising filovirus vaccines under development is a system based on recombinant vesicular stomatitis virus (rVSV) that expresses an individual filovirus glycoprotein (GP) in place of the VSV glycoprotein (G).

Recombinant Vesicular Stomatitis Virus Vaccine Vectors ~ Abstract The filoviruses, Marburg virus and Ebola virus, cause severe hemorrhagic fever with high mortality in humans and nonhuman primates. Among the most promising filovirus vaccines under development is a system based on recombinant vesicular stomatitis virus (rVSV) that expresses an individual filovirus glycoprotein (GP) in place of the VSV glycoprotein (G).

Recombinant Vesicular Stomatitis Virus–Based Vaccines ~ Among the most-promising filovirus vaccines under development is a system based on recombinant vesicular stomatitis virus (rVSV) that expresses a single filovirus glycoprotein (GP) in place of the VSV glycoprotein (G).

Recombinant Vesicular Stomatitis Virus–Based Vaccines ~ The filoviruses, Marburg virus and Ebola virus, cause severe hemorrhagic fever with a high mortality rate in humans and nonhuman primates. Among the most-promising filovirus vaccines under development is a system based on recombinant vesicular stomatitis virus (rVSV) that expresses a single filovirus glycoprotein (GP) in place of the VSV glycoprotein (G).

Use of Single-Injection Recombinant Vesicular Stomatitis ~ Nipah virus (NiV) and Hendra virus (HeV) are highly pathogenic zoonotic agents in the paramyxovirus genus Henipavirus.Human case-fatality rates (CFRs) for these viruses historically have ranged from 40% to >90% ().NiV is categorized as a Biosafety Level 4 (BSL-4) pathogen because of the substantial illness and death it causes and the lack of approved vaccines and therapeutic drugs for human use.

Recombinant Vesicular Stomatitis Virus Vector Mediates ~ Recombinant vesicular stomatitis virus (VSV) vectors expressing homologous filoviral glycoproteins can completely protect rhesus monkeys against Marburg virus when administered after exposure and can partially protect macaques after challenge with Zaire ebolavirus.Here, we administered a VSV vector expressing the Sudan ebolavirus (SEBOV) glycoprotein to four rhesus macaques shortly after .

A Recombinant Vesicular Stomatitis Virus Ebola Vaccine / NEJM ~ Mire CE, Miller AD, Carville A, et al. Recombinant vesicular stomatitis virus vaccine vectors expressing filovirus glycoproteins lack neurovirulence in nonhuman primates. PLoS Negl Trop Dis 2012 .

Clinical development of a recombinant Ebola vaccine in the ~ The V920 vaccine candidate is a live-attenuated, chimeric virus which is based on a recombinant vesicular stomatitis virus (rVSV) backbone. In V920 the G glycoprotein of the rVSV is deleted and completely replaced by the glycoprotein (GP) of Zaire ebolavirus (rVSVΔG-ZEBOV-GP) attenuating the virus .This substitution eliminates the neurovirulence associated with wild type VSV and is believed .

Durability of a Vesicular Stomatitis Virus-Based Marburg ~ The filoviruses, Marburg virus (MARV) and Ebola virus, causes severe hemorrhagic fever with high mortality in humans and nonhuman primates. A promising filovirus vaccine under development is based on a recombinant vesicular stomatitis virus (rVSV) that expresses individual filovirus glycoproteins (GPs) in place of the VSV glycoprotein (G).

Vesicular Stomatitis Virus-Based Vaccines Protect Nonhuman ~ Replication-competent, recombinant vesicular stomatitis virus (rVSV) vectors expressing filovirus glycoproteins (GP), in place of the VSV glycoprotein have shown promise in lethal nonhuman primate (NHP) models of filovirus infection as both single injection preventive vaccines and as post-exposure treatments.

Use of Single-Injection Recombinant Vesicular Stomatitis ~ recombinant measles virus vector expressing the NiV M G Use of Single-Injection Recombinant Vesicular Stomatitis Virus Vaccine to Protect Nonhuman Primates Against Lethal Nipah Virus Disease Chad E. Mire, Joan B. Geisbert, Krystle N. Agans, Krista M. Versteeg, Daniel J. Deer, Benjamin A. Satterfield,1 Karla A. Fenton, Thomas W. Geisbert

Vesicular stomatitis virus-based vaccines protect nonhuman ~ Among the most promising vaccines is a system based on recombinant vesicular stomatitis virus (VSV) which not only can protect nonhuman primates against EBOV and MARV when used as a single injection preventive vaccine but astonishingly showed 50–100% efficacy when employed as a postexposure treatment , , .

Pregnancy Outcomes among Women Receiving rVSVΔ-ZEBOV-GP ~ Mire CE, Miller AD, Carville A, Westmoreland SV, Geisbert JB, Mansfield KG, et al. Recombinant vesicular stomatitis virus vaccine vectors expressing filovirus glycoproteins lack neurovirulence in nonhuman primates. PLoS Negl Trop Dis. 2012; 6: e1567. DOI PubMed

Immunization with vesicular stomatitis virus vaccine ~ 4.2. Production of vesicular stomatitis virus-vectored vaccine. The recombinant VSV expressing EBOV GP was generated as described previously, using the infectious clone for VSV Indiana serotype . Briefly, the open reading frame for EBOV GP was generated using polymerase chain reaction and cloned into the VSV plasmid lacking its wild-type .

Single dose attenuated Vesiculovax vaccines protect ~ Mire CE, et al. Recombinant vesicular stomatitis virus vaccine vectors expressing filovirus glycoproteins lack neurovirulence in nonhuman primates. PLoS Negl Trop Dis. 2012; 6:e1567. [PMC free article]

Safety of Recombinant VSV–Ebola Virus Vaccine Vector in ~ The ongoing Ebola outbreak in West Africa has resulted in fast-track development of vaccine candidates. We tested a vesicular stomatitis virus vector expressing Ebola virus glycoprotein for safety in pigs. Inoculation did not cause disease and vaccine virus shedding was minimal, which indicated that the vaccine virus does not pose a risk of dissemination in pigs.

(PDF) Safety of Recombinant VSV–Ebola Virus Vaccine Vector ~ Among the most-promising filovirus vaccines under development is a system based on recombinant vesicular stomatitis virus (rVSV) that expresses a single filovirus glycoprotein (GP) in place of the .

Immunogenicity, Lot Consistency, and Extended Safety of ~ Recombinant vesicular stomatitis virus vaccine vectors expressing filovirus glycoproteins lack neurovirulence in nonhuman primates. PLoS Negl Trop Dis. 2012; 6: e1567. . Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses.

Ebolavirus in West Africa, and the use of experimental ~ Mire CE, Miller AD, Carville A, Westmoreland SV, Geisbert JB, Mansfield KG, Feldmann H, Hensley LE, Geisbert TW: Recombinant vesicular stomatitis virus vaccine vectors expressing filovirus glycoproteins lack neurovirulence in nonhuman primates.PLoS Negl Trop Dis 2012, 6:e1567.,

Use of Single-Injection Recombinant Vesicular Stomatitis ~ Nipah virus (NiV) is a zoonotic pathogen that causes high case-fatality rates (CFRs) in humans. Two NiV strains have caused outbreaks: the Malaysia strain (NiVM), discovered in 1998–1999 in Malaysia and Singapore (≈40% CFR); and the Bangladesh strain (NiVB), discovered in Bangladesh and India in 2001 (≈80% CFR). Recently, NiVB in African green monkeys resulted in a more severe and lethal .